Partnership to advance digital biomarker platform for Parkinson’s disease
A Swiss-based medical technology company has announced a partnership with Biogen to advance a digital biomarker platform involved in a planned clinical trial for BIIB122, a novel therapeutic to treat Parkinson’s disease.
According to a release from Indivi, the agreement stipulates that Biogen will license Konectom, a smartphone-based platform to its new partner, also granting Indivi digital management of the platform in the phase 2b LUMA study, which will evaluate safety and efficacy of BIIB122, a small molecule inhibitor, in participants with early-stage PD.
A new partnership seeks to promote a digital biomarker platform that features prominently in a phase 2b study of a novel therapeutic for Parkinson’s disease.
Under additional terms of the partnership, Indivi is expected to control deployment of Konectom in matters of service availability, development, maintenance, algorithm development and data processing to generate derived digital measures from the LUMA study.
Biogen and Indivi have also agreed, per the release, to develop and validate novel digital endpoints in PD as well as to leverage technology within Konectom to explore additional disease areas for endpoint development.
“We aim to expand the reach of our unique technology to a new critical disease area where innovation is crucially needed and that may cross-fertilize with the progress of our scientific efforts in MS,” Indivi CEO Guilhem Dupont said in the release. “This collaboration is a testament to the hard work and dedication of our entire team over the past 5 years in developing transformative digital measurements to support research in neuroscience."
April 3, 2024
